Starling Oncology expects $650M-$660M revenue and $4M-$6M adjusted EBITDA in 2026 while targeting 100% capitated revenue growth in 2027

Seeking Alpha · 市场快讯 · November 6, 2026 at 11:55 AM ET

Read the full report at the original publisher.